Investors & Media
Bardoxolone methyl

Bardoxolone methyl, previously known as RTA 402,
is the lead molecule in Reata's portfolio of
AIMs
Image by Wyman Meinzer
Home |
Investors & Media |
News |
Phase 1 Cancer Results with RTA 402 Scheduled for Oral Presentation at 2008 ASCO
